Which has better earnings & valuation, HNGE or ASTH?

Astrana Health has higher revenue and earnings than Hinge Health. Astrana Health is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hinge Health $587.86M 12.14 -$528.26M $1.28 69.09 Astrana Health $3.84B 0.57 $22.49M $0.82 47.99

Does the media refer more to HNGE or ASTH?

In the previous week, Hinge Health had 7 more articles in the media than Astrana Health. MarketBeat recorded 10 mentions for Hinge Health and 3 mentions for Astrana Health. Astrana Health's average media sentiment score of 0.94 beat Hinge Health's score of 0.90 indicating that Astrana Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hinge Health 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Astrana Health 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, ASTH or CHE?

Chemed has lower revenue, but higher earnings than Astrana Health. Chemed is trading at a lower price-to-earnings ratio than Astrana Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrana Health $3.84B 0.57 $22.49M $0.82 47.99 Chemed $2.53B 2.80 $265.24M $19.91 27.19

Is ASTH or CHE more profitable?

Chemed has a net margin of 10.60% compared to Astrana Health's net margin of 1.05%. Chemed's return on equity of 31.77% beat Astrana Health's return on equity. Company Net Margins Return on Equity Return on Assets Astrana Health 1.05% 10.30% 3.67% Chemed 10.60% 31.77% 18.90%

Does the media refer more to ASTH or CHE?

In the previous week, Chemed had 1 more articles in the media than Astrana Health. MarketBeat recorded 4 mentions for Chemed and 3 mentions for Astrana Health. Chemed's average media sentiment score of 1.58 beat Astrana Health's score of 0.94 indicating that Chemed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrana Health 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Chemed 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to ASTH or HIMS?

In the previous week, Hims & Hers Health had 39 more articles in the media than Astrana Health. MarketBeat recorded 42 mentions for Hims & Hers Health and 3 mentions for Astrana Health. Astrana Health's average media sentiment score of 0.94 beat Hims & Hers Health's score of 0.22 indicating that Astrana Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrana Health 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 12 Very Positive mention(s) 4 Positive mention(s) 15 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, RDNT or ASTH?

Astrana Health has higher revenue and earnings than RadNet. RadNet is trading at a lower price-to-earnings ratio than Astrana Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RadNet $2.04B 2.96 -$18.65M -$0.27 N/A Astrana Health $3.84B 0.57 $22.49M $0.82 47.99

Is RDNT or ASTH more profitable?

Astrana Health has a net margin of 1.05% compared to RadNet's net margin of -0.93%. Astrana Health's return on equity of 10.30% beat RadNet's return on equity. Company Net Margins Return on Equity Return on Assets RadNet -0.93% 2.61% 0.91% Astrana Health 1.05% 10.30% 3.67%

Does the media refer more to RDNT or ASTH?

In the previous week, RadNet had 2 more articles in the media than Astrana Health. MarketBeat recorded 5 mentions for RadNet and 3 mentions for Astrana Health. RadNet's average media sentiment score of 1.72 beat Astrana Health's score of 0.94 indicating that RadNet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RadNet 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Astrana Health 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LFST or ASTH?

In the previous week, LifeStance Health Group had 4 more articles in the media than Astrana Health. MarketBeat recorded 7 mentions for LifeStance Health Group and 3 mentions for Astrana Health. Astrana Health's average media sentiment score of 0.94 beat LifeStance Health Group's score of 0.70 indicating that Astrana Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LifeStance Health Group 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Astrana Health 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Astrana Health (ASTH) Competitors

$39.35 +0.61 (+1.57%)

As of 08/21/2026 04:00 PM Eastern

Compare

ASTH vs. HNGE, CHE, HIMS, RDNT, and LFST

Should you buy Astrana Health stock or one of its competitors? Astrana Health's main competitors and comparable companies include Hinge Health (HNGE), Chemed (CHE), Hims & Hers Health (HIMS), RadNet (RDNT), and LifeStance Health Group (LFST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Astrana Health compare to Hinge Health?

Hinge Health (NYSE:HNGE) and Astrana Health (NASDAQ:ASTH) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

In the previous week, Hinge Health had 7 more articles in the media than Astrana Health. MarketBeat recorded 10 mentions for Hinge Health and 3 mentions for Astrana Health. Astrana Health's average media sentiment score of 0.94 beat Hinge Health's score of 0.90 indicating that Astrana Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hinge Health	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Astrana Health	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hinge Health has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, Astrana Health has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

Astrana Health has higher revenue and earnings than Hinge Health. Astrana Health is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hinge Health	$587.86M	12.14	-$528.26M	$1.28	69.09
Astrana Health	$3.84B	0.57	$22.49M	$0.82	47.99

52.8% of Astrana Health shares are owned by institutional investors. 18.9% of Hinge Health shares are owned by insiders. Comparatively, 20.3% of Astrana Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Hinge Health has a net margin of 15.15% compared to Astrana Health's net margin of 1.05%. Hinge Health's return on equity of 51.60% beat Astrana Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hinge Health	15.15%	51.60%	14.16%
Astrana Health	1.05%	10.30%	3.67%

Hinge Health presently has a consensus target price of $100.57, suggesting a potential upside of 13.72%. Astrana Health has a consensus target price of $49.43, suggesting a potential upside of 25.61%. Given Astrana Health's higher probable upside, analysts plainly believe Astrana Health is more favorable than Hinge Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hinge Health	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Astrana Health	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

Hinge Health beats Astrana Health on 11 of the 17 factors compared between the two stocks.

How does Astrana Health compare to Chemed?

Astrana Health (NASDAQ:ASTH) and Chemed (NYSE:CHE) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

Astrana Health currently has a consensus price target of $49.43, suggesting a potential upside of 25.61%. Chemed has a consensus price target of $530.75, suggesting a potential downside of 1.95%. Given Astrana Health's stronger consensus rating and higher probable upside, analysts clearly believe Astrana Health is more favorable than Chemed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrana Health	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

Chemed has lower revenue, but higher earnings than Astrana Health. Chemed is trading at a lower price-to-earnings ratio than Astrana Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrana Health	$3.84B	0.57	$22.49M	$0.82	47.99
Chemed	$2.53B	2.80	$265.24M	$19.91	27.19

Astrana Health has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, Chemed has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

Chemed has a net margin of 10.60% compared to Astrana Health's net margin of 1.05%. Chemed's return on equity of 31.77% beat Astrana Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrana Health	1.05%	10.30%	3.67%
Chemed	10.60%	31.77%	18.90%

52.8% of Astrana Health shares are owned by institutional investors. Comparatively, 95.9% of Chemed shares are owned by institutional investors. 20.3% of Astrana Health shares are owned by company insiders. Comparatively, 3.3% of Chemed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Chemed had 1 more articles in the media than Astrana Health. MarketBeat recorded 4 mentions for Chemed and 3 mentions for Astrana Health. Chemed's average media sentiment score of 1.58 beat Astrana Health's score of 0.94 indicating that Chemed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrana Health	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Chemed	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Chemed beats Astrana Health on 9 of the 16 factors compared between the two stocks.

How does Astrana Health compare to Hims & Hers Health?

Astrana Health (NASDAQ:ASTH) and Hims & Hers Health (NYSE:HIMS) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

52.8% of Astrana Health shares are owned by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are owned by institutional investors. 20.3% of Astrana Health shares are owned by insiders. Comparatively, 11.8% of Hims & Hers Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Astrana Health has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.4, suggesting that its share price is 140% more volatile than the broader market.

Hims & Hers Health has lower revenue, but higher earnings than Astrana Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Astrana Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrana Health	$3.84B	0.57	$22.49M	$0.82	47.99
Hims & Hers Health	$2.35B	3.35	$128.37M	-$0.63	N/A

Astrana Health has a net margin of 1.05% compared to Hims & Hers Health's net margin of -5.51%. Astrana Health's return on equity of 10.30% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrana Health	1.05%	10.30%	3.67%
Hims & Hers Health	-5.51%	-6.51%	-1.20%

In the previous week, Hims & Hers Health had 39 more articles in the media than Astrana Health. MarketBeat recorded 42 mentions for Hims & Hers Health and 3 mentions for Astrana Health. Astrana Health's average media sentiment score of 0.94 beat Hims & Hers Health's score of 0.22 indicating that Astrana Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrana Health	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hims & Hers Health	12 Very Positive mention(s)	4 Positive mention(s)	15 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

Astrana Health presently has a consensus target price of $49.43, suggesting a potential upside of 25.61%. Hims & Hers Health has a consensus target price of $32.17, suggesting a potential downside of 4.46%. Given Astrana Health's stronger consensus rating and higher possible upside, equities analysts plainly believe Astrana Health is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrana Health	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Hims & Hers Health	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.19

Summary

Astrana Health beats Hims & Hers Health on 11 of the 16 factors compared between the two stocks.

How does Astrana Health compare to RadNet?

RadNet (NASDAQ:RDNT) and Astrana Health (NASDAQ:ASTH) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Astrana Health has a net margin of 1.05% compared to RadNet's net margin of -0.93%. Astrana Health's return on equity of 10.30% beat RadNet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RadNet	-0.93%	2.61%	0.91%
Astrana Health	1.05%	10.30%	3.67%

77.9% of RadNet shares are held by institutional investors. Comparatively, 52.8% of Astrana Health shares are held by institutional investors. 5.1% of RadNet shares are held by company insiders. Comparatively, 20.3% of Astrana Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

RadNet has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, Astrana Health has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

Astrana Health has higher revenue and earnings than RadNet. RadNet is trading at a lower price-to-earnings ratio than Astrana Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RadNet	$2.04B	2.96	-$18.65M	-$0.27	N/A
Astrana Health	$3.84B	0.57	$22.49M	$0.82	47.99

In the previous week, RadNet had 2 more articles in the media than Astrana Health. MarketBeat recorded 5 mentions for RadNet and 3 mentions for Astrana Health. RadNet's average media sentiment score of 1.72 beat Astrana Health's score of 0.94 indicating that RadNet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RadNet	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Astrana Health	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

RadNet currently has a consensus price target of $88.00, suggesting a potential upside of 14.55%. Astrana Health has a consensus price target of $49.43, suggesting a potential upside of 25.61%. Given Astrana Health's higher probable upside, analysts plainly believe Astrana Health is more favorable than RadNet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RadNet	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Astrana Health	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

Astrana Health beats RadNet on 10 of the 17 factors compared between the two stocks.

How does Astrana Health compare to LifeStance Health Group?

LifeStance Health Group (NASDAQ:LFST) and Astrana Health (NASDAQ:ASTH) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

85.5% of LifeStance Health Group shares are held by institutional investors. Comparatively, 52.8% of Astrana Health shares are held by institutional investors. 3.5% of LifeStance Health Group shares are held by company insiders. Comparatively, 20.3% of Astrana Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

LifeStance Health Group has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market. Comparatively, Astrana Health has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

LifeStance Health Group has a net margin of 3.19% compared to Astrana Health's net margin of 1.05%. Astrana Health's return on equity of 10.30% beat LifeStance Health Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeStance Health Group	3.19%	3.39%	2.33%
Astrana Health	1.05%	10.30%	3.67%

In the previous week, LifeStance Health Group had 4 more articles in the media than Astrana Health. MarketBeat recorded 7 mentions for LifeStance Health Group and 3 mentions for Astrana Health. Astrana Health's average media sentiment score of 0.94 beat LifeStance Health Group's score of 0.70 indicating that Astrana Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LifeStance Health Group	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Astrana Health	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LifeStance Health Group currently has a consensus target price of $12.38, suggesting a potential downside of 0.76%. Astrana Health has a consensus target price of $49.43, suggesting a potential upside of 25.61%. Given Astrana Health's stronger consensus rating and higher probable upside, analysts plainly believe Astrana Health is more favorable than LifeStance Health Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeStance Health Group	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
Astrana Health	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Astrana Health has higher revenue and earnings than LifeStance Health Group. Astrana Health is trading at a lower price-to-earnings ratio than LifeStance Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeStance Health Group	$1.42B	3.40	$9.66M	$0.13	95.92
Astrana Health	$3.84B	0.57	$22.49M	$0.82	47.99

Summary

Astrana Health beats LifeStance Health Group on 10 of the 17 factors compared between the two stocks.

Get Astrana Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASTH vs. The Competition

Export

Metric	Astrana Health	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.19B	$9.83B	$7.36B	$12.84B
Dividend Yield	N/A	2.55%	2.54%	11.08%
P/E Ratio	47.99	34.38	272.88	24.24
Price / Sales	0.57	4.97	621.86	100.14
Price / Cash	13.99	125.12	78.62	53.99
Price / Book	2.61	4.05	13.05	6.20
Net Income	$22.49M	$311.06M	$3.47B	$348.59M
7 Day Performance	-3.58%	0.83%	2.09%	0.08%
1 Month Performance	-4.00%	2.42%	6.64%	3.88%
1 Year Performance	28.26%	15.69%	25.02%	16.98%

Astrana Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASTH Astrana Health	3.9659 of 5 stars	$39.35 +1.6%	$49.43 +25.6%	+28.3%	$2.19B	$3.84B	47.99	3,000
HNGE Hinge Health	3.7347 of 5 stars	$88.44 +0.6%	$100.57 +13.7%	+53.9%	$7.14B	$587.86M	69.09	1,437	Insider Trade
CHE Chemed	4.0452 of 5 stars	$529.94 +0.9%	$530.75 +0.2%	+17.7%	$6.96B	$2.53B	26.62	15,811	Positive News
HIMS Hims & Hers Health	1.8522 of 5 stars	$27.43 -4.1%	$32.43 +18.3%	-24.4%	$6.57B	$2.35B	N/A	2,442	Trending News Analyst Forecast Insider Trade
RDNT RadNet	3.1258 of 5 stars	$73.83 -2.8%	$88.00 +19.2%	+9.6%	$6.01B	$2.04B	N/A	11,264	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASTH) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Astrana Health (ASTH) Competitors

ASTH vs. HNGE, CHE, HIMS, RDNT, and LFST

How does Astrana Health compare to Hinge Health?

Summary

How does Astrana Health compare to Chemed?

Summary

How does Astrana Health compare to Hims & Hers Health?

Summary

How does Astrana Health compare to RadNet?

Summary

How does Astrana Health compare to LifeStance Health Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASTH vs. The Competition

Astrana Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Astrana Health (ASTH) Competitors

ASTH vs. HNGE, CHE, HIMS, RDNT, and LFST

How does Astrana Health compare to Hinge Health?

Does the media refer more to HNGE or ASTH?

Which has more risk & volatility, HNGE or ASTH?

Which has better earnings & valuation, HNGE or ASTH?

Do insiders and institutionals hold more shares of HNGE or ASTH?

Is HNGE or ASTH more profitable?

Do analysts recommend HNGE or ASTH?

Summary

How does Astrana Health compare to Chemed?

Do analysts recommend ASTH or CHE?

Which has higher valuation & earnings, ASTH or CHE?

Which has more volatility & risk, ASTH or CHE?

Is ASTH or CHE more profitable?

Do insiders & institutionals hold more shares of ASTH or CHE?

Does the media refer more to ASTH or CHE?

Summary

How does Astrana Health compare to Hims & Hers Health?

Do institutionals and insiders hold more shares of ASTH or HIMS?

Which has more volatility and risk, ASTH or HIMS?

Which has preferable valuation and earnings, ASTH or HIMS?

Is ASTH or HIMS more profitable?

Does the media refer more to ASTH or HIMS?

Do analysts recommend ASTH or HIMS?

Summary

How does Astrana Health compare to RadNet?

Is RDNT or ASTH more profitable?

Do institutionals & insiders hold more shares of RDNT or ASTH?

Which has more risk and volatility, RDNT or ASTH?

Which has preferable valuation & earnings, RDNT or ASTH?

Does the media refer more to RDNT or ASTH?

Do analysts rate RDNT or ASTH?

Summary

How does Astrana Health compare to LifeStance Health Group?

Do insiders & institutionals believe in LFST or ASTH?

Which has more volatility and risk, LFST or ASTH?

Is LFST or ASTH more profitable?

Does the media prefer LFST or ASTH?

Do analysts rate LFST or ASTH?

Which has higher valuation and earnings, LFST or ASTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASTH vs. The Competition

Astrana Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools